Eton Pharmaceuticals (ETON) vs Korsana Biosciences (KRSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Korsana Biosciences (KRSA) over the past year, gaining 161.6% versus a gain of 90.0%. Over five years, ETON leads with a +950.9% price change compared with -91.1% for KRSA. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.53 billion), about 1.0 times the size.
Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -170.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | KRSA |
|---|---|---|
| Share price | $54.75 | $33.51 |
| Market cap | $1.56B | $1.53B |
| 1-day change | -0.24% | +6.37% |
| YTD return | +223.77% | +276.94% |
| 1-year return | +161.59% | +89.97% |
| 5-year return | +950.86% | -91.10% |
| P/E ratio (TTM) | 136.88 | — |
| Forward P/E | 21.22 | — |
| EPS (TTM) | $0.40 | $-7.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $2.07M |
| Revenue growth (YoY) | +104.94% | +3.70% |
| Net income (latest FY) | $-4.60M | $-3.53M |
| Gross margin | 53.46% | — |
| Operating margin | -1.06% | -239.78% |
| Net margin | -5.75% | -170.11% |
| 52-week high | $66.37 | $59.36 |
| 52-week low | $14.27 | $7.19 |
| Distance from 52-week high | -17.51% | -43.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +31.30% |
| Average volume | 609.36K | 32.06K |
| Shares outstanding | 28.58M | 45.54M |
| Employees | 44 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed KRSA by 71.6 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +3.70%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
ETON vs KRSA FAQ
Which is bigger, Eton Pharmaceuticals or Korsana Biosciences?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $1.53B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, ETON or KRSA?
ETON returned +161.59% over the past 12 months, compared with +89.97% for KRSA (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Korsana Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.